Docoh
Loading...

EBAC European Biotech Acquisition

Filed: 4 May 21, 4:33pm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 4, 2021

European Biotech Acquisition Corp.

(Exact name of registrant as specified in its charter)

Cayman Islands001-40211N/A

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

 

Johannes Vermeerplein 9

1071 DV Amsterdam, Netherlands

N/A
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: 31 (0) 20 664 55 00

 

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Class A ordinary shares, par value $0.0001 per share EBAC The Nasdaq Capital Market
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 EBACW The Nasdaq Capital Market
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant EBACU The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01. Other Events.  

 

On May 4, 2021, European Biotech Acquisition Corp. (the “Company”) announced that the holders of the Company’s units (the “Units”) may elect to separately trade the Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), and warrants included in the Units commencing on May 6, 2021. Each Unit consists of one Class A ordinary share and one-third of one warrant to purchase one Class A ordinary share. Any Units not separated will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EBACU”. Any underlying shares of Class A ordinary shares and warrants that are separated will trade on Nasdaq under the symbols “EBAC” and “EBACW,” respectively. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the holders’ Units into Class A ordinary shares and warrants.

 

A copy of the press release issued by the Company announcing the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1.

 

 

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

EXHIBIT INDEX

Exhibit

No.

 Description
   
99.1 Press Release, dated May 4, 2021.

 

 

 

 

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 4, 2021

 

 

EUROPEAN BIOTECH ACQUISITION CORP.

 

  
 By:/s/ Eduardo Bravo
 Name:    Eduardo Bravo
 Title: Chief Executive Officer